NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio’s ANVS-25002 open-label Parkinson’s disease clinical trial. NeuroRPM’s platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson’s motor symptoms. The ANVS-25002 study is expected to enroll approximately 500 participants with Parkinson’s disease across multiple clinical sites. Eligible participants may choose to take part in the NeuroRPM digital monitoring program to complement scheduled study assessments with continuous real-world symptom monitoring. Parkinson’s symptoms often fluctuate throughout the day and vary across patients, making treatment response difficult to fully characterize through periodic in-clinic assessments alone. NeuroRPM a
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease StudyGlobeNewswire
- Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial ResultsGlobeNewswire
- Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference [Yahoo! Finance]Yahoo! Finance
- Annovis Announces Two Presentations at the AD/PD™ 2026 International ConferenceGlobeNewswire
ANVS
Sec Filings
- 3/16/26 - Form 8-K
- 3/13/26 - Form 10-K
- 2/12/26 - Form 8-K
- ANVS's page on the SEC website